Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Urothelial Carcinoma Diagnostics
Advertisement
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
Video Insights
Conference Coverage
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.